Protective Effects of Ticagrelor on Myocardial Injury After Infarction

Area of Science:

• Cardiology
• Pharmacology
• Biochemistry

Background:

• Ticagrelor demonstrates superior clinical outcomes to clopidogrel post-myocardial infarction (MI).
• Potential off-target effects of ticagrelor via adenosine pathways are hypothesized.
• Mechanisms underlying ticagrelor's enhanced efficacy require elucidation.

Purpose of the Study:

• To compare the extent of myocardial injury reduction by ticagrelor versus clopidogrel after MI.
• To investigate the role of adenosine-mediated mechanisms in ticagrelor's cardioprotection.
• To assess molecular changes in the myocardium associated with each drug.

Main Methods:

• Pigs underwent myocardial infarction (MI) and received placebo, clopidogrel, ticagrelor, or ticagrelor plus an adenosine receptor antagonist.
• Cardiac MRI, platelet aggregation assays, and myocardial tissue analysis (protein expression, enzyme activity) were performed.
• Specific proteins evaluated included aquaporin-4, AMP-activated protein kinase, and cyclooxygenase-2.

Main Results:

• Both ticagrelor and clopidogrel provided significant antiplatelet effects and reduced infarct size compared to placebo.
• Ticagrelor achieved a significantly greater reduction in infarct size (23.5% more than clopidogrel) and myocardial edema (24.5% less).
• Adenosine receptor blockade abolished ticagrelor's superior cardioprotective effects, implicating adenosine pathways and altered molecular signaling.

Conclusions:

• Ticagrelor offers significant cardioprotection by reducing necrotic injury and edema formation post-MI.
• These beneficial effects are mediated through adenosine-dependent mechanisms, independent of platelet inhibition levels.
• Ticagrelor's action involves modulation of aquaporin-4, AMPK, and COX-2 signaling in the ischemic myocardium.